Staff of the Healthy Mind Lab at Washington University School of Medicine in St. Louis pack medication and medical equipment for participants in a COVID-19 clinical trial. The study indicated that the drug fluvoxamine may help prevent deterioration in COVID-19 patients, making hospitalization less likely.
Fluvoxamine may prevent serious illness in COVID-19 patients
In a preliminary study of COVID-19 patients with mild-to-moderate disease who were attempting to recover in their homes, researchers at Washington University School of Medicine in St. Louis have found that the drug fluvoxamine seems to prevent some of the most serious complications of the illness and make hospitalization and the need for supplemental oxygen less likely.
The study, a collaboration between the university’s Department of Psychiatry and Division of Infectious Diseases, involved 152 patients infected with SARS-CoV-2, the virus that causes COVID-19. Researchers compared the outcomes of those treated with fluvoxamine to the outcomes of those given an inactive placebo. After 15 days, none of the 80 patients who had received the drug experienced serious clinical deterioration. Meanwhile, six of the 72 patients given placebo (8.3%) became seriously ill, with four requiring hospitalization.
The study is published online Nov. 12 in the Journal of the American Medical Association.
“The patients who took fluvoxamine did not develop serious breathing difficulties or require hospitalization for problems with lung function,” said the paper’s first author, Eric J. Lenze, MD, the Wallace and Lucille Renard Professor of Psychiatry. “Most investigational treatments for COVID-19 have been aimed at the very sickest patients, but it’s also important to find therapies that prevent patients from getting sick enough to require supplemental oxygen or to have to go to the hospital. Our study suggests fluvoxamine may help fill that niche.”
Fluvoxamine is used commonly to treat obsessive-compulsive disorder (OCD), social anxiety disorder and depression. It is in a class of drugs known as selective serotonin-reuptake inhibitors (SSRIs), but unlike other SSRIs, fluvoxamine interacts strongly with a protein called the sigma-1 receptor. That receptor also helps regulate the body’s inflammatory response.
“There are several ways this drug might work to help COVID-19 patients, but we think it most likely may be interacting with the sigma-1 receptor to reduce the production of inflammatory molecules,” said senior author Angela M Reiersen, MD, an associate professor of psychiatry. “Past research has demonstrated that fluvoxamine can reduce inflammation in animal models of sepsis, and it may be doing something similar in our patients.”
Reiersen said the drug’s effects on inflammation could prevent the immune system from mounting an overwhelming response, which is thought to occur in some COVID-19 patients who seem to improve after a few days of illness and then worsen. Many of those patients end up hospitalized, and some die.
In an innovative twist to research during the pandemic, the study was conducted remotely. When a symptomatic patient tested positive and enrolled in the study, research staff delivered the medication or inactive placebo to them, along with thermometers, automatic blood pressure monitors and fingertip oxygen sensors.
“Our goal is to help patients who are initially well enough to be at home and to prevent them from getting sick enough to be hospitalized,” said Caline Mattar, MD, an assistant professor of medicine in the Division of Infectious Diseases. “What we’ve seen so far suggests that fluvoxamine may be an important tool in achieving that goal.”
For two weeks, subjects took either the antidepressant drug or placebo sugar pills while having daily interactions with members of the research team — via phone or computer. That allowed patients to report on their symptoms, oxygen levels and other vital signs. If patients suffered shortness of breath or were hospitalized for pneumonia, or their oxygen saturation levels fell below 92%, their conditions were considered to have deteriorated.
“The good news is that not a single person taking the active medication experienced deterioration,” Reiersen said. “We believe this drug may be the reason, but we need to study more patients to make sure.”
The researchers will begin a larger study in the next few weeks. Lenze, the director of the Healthy Mind Lab at the School of Medicine, is an expert in using mobile and internet technology to conduct clinical trials. He said that although this initial study involved patients in the St. Louis region, the next phase of the research will involve patients from throughout the country.
“We bring the study to the patients, giving them tools to monitor their health at home,” Lenze said. “Our hope is that we can keep these patients healthy enough to avoid hospitalization.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Trial based on UVa research shows antidepressant may lessen COVID-19 symptomson November 21, 2020 at 5:50 am
The trial, conducted by the Washington University School of Medicine in St. Louis, compared outcomes of those taking fluvoxamine with effects of the coronavirus. The trial focused on 152 patients ...
- Repurposed Antidepressant Shows Early Promise in COVID-19on November 19, 2020 at 10:56 am
Early treatment with the antidepressant fluvoxamine (Luvox) may help prevent respiratory deterioration in patients with mild symptomatic COVID-19, results of a preliminary randomized controlled ...
- Fluvoxamine Linked to Reduction in Clinical Deterioration in COVID-19on November 19, 2020 at 4:14 am
(HealthDay News) — For adult outpatients with COVID-19, fluvoxamine is associated with a reduction in clinical deterioration, according to a study published online Nov. 12 in the Journal of the ...
- How a Medication for OCD Ended Up in a Covid-19 Trialon November 18, 2020 at 11:00 pm
Fluvoxamine is a selective serotonin reuptake inhibitor, or SSRI, and it’s typically prescribed for obsessive-compulsive disorder. Fast forward to March. As the pandemic rolled in, Reiersen came ...
- Antidepressant Drug Helps Prevent Deterioration in Patients With COVID-19on November 18, 2020 at 1:38 pm
Fluvoxamine was not intended as a COVID-19 medication, but a recent study suggests it may help prevent serious complications for patients with COVID-19.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Preventing serious Covid-19 illness
- Address issue of crowded, confined accommodation of foreign workers to curb spread of COVID-19 - Health D-Gon November 29, 2020 at 1:57 am
KUALA LUMPUR, Nov 29 -- The issue of crowded and confined accommodation of foreign workers needs to be tackled immediately to ensure that it does cause the spread of COVID-19 and other infectious ...
- SLO County Public Health reports 36th coronavirus-related deathon November 27, 2020 at 1:26 pm
The San Luis Obispo County Public Health Department announced Friday that a 36th resident has passed away from COVID-19.
- These at-home exercises can help older people boost their immune system and overall health in the age of COVID-19on November 26, 2020 at 3:35 pm
Older adults, especially those over 65, have five times the risk of hospitalization and 90 times the risk of death from COVID-19 compared with younger adults. According to the U.S. Centers for Disease ...
- Indiana hospitals begin new COVID-19 treatment from Eli Lilly to prevent serious symptoms, hospitalizationson November 25, 2020 at 12:21 am
IU Health and other hospitals around the state are beginning to administer Eli Lilly’s COVID-19 treatment, bamlanivimab. The treatment is for COVID-19 patients with mild ...
- Drug Used to Treat OCD Can Prevent Serious Illness in COVID-19 Patientson November 13, 2020 at 11:05 pm
Researchers have found that the drug fluvoxamine seems to prevent some of the most serious complications of the illness from Covid-19 and make hospitalization and the need for supplemental oxygen ...